Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $8.65 million. The enterprise value is $12.53 million.
| Market Cap | 8.65M |
| Enterprise Value | 12.53M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, before market open.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 5.09 million shares outstanding. The number of shares has increased by 46.29% in one year.
| Shares Outstanding | 5.09M |
| Shares Change (YoY) | +46.29% |
| Shares Change (QoQ) | +13.13% |
| Owned by Insiders (%) | 28.19% |
| Owned by Institutions (%) | 39.15% |
| Float | 2.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.25 |
| Forward PS | 0.21 |
| PB Ratio | 1.78 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 1.13.
| Current Ratio | 1.28 |
| Quick Ratio | 0.36 |
| Debt / Equity | 1.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.99 |
Financial Efficiency
Return on equity (ROE) is -270.60% and return on invested capital (ROIC) is -221.52%.
| Return on Equity (ROE) | -270.60% |
| Return on Assets (ROA) | -57.10% |
| Return on Capital (ROIC) | -221.52% |
| Revenue Per Employee | $410,494 |
| Profits Per Employee | -$242,542 |
| Employee Count | 83 |
| Asset Turnover | 0.97 |
| Inventory Turnover | 1.93 |
Taxes
In the past 12 months, Biofrontera has paid $14,000 in taxes.
| Income Tax | 14,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.24% in the last 52 weeks. The beta is 0.84, so Biofrontera's price volatility has been lower than the market average.
| Beta (1Y) | 0.84 |
| 52-Week Price Change | -86.24% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 4.90 |
| Relative Strength Index (RSI) | 50.57 |
| Average Volume (30 Days) | 791,719 |
Short Selling Information
The latest short interest is 34,771, so 0.68% of the outstanding shares have been sold short.
| Short Interest | 34,771 |
| Short Previous Month | 84,235 |
| Short % of Shares Out | 0.68% |
| Short % of Float | 1.74% |
| Short Ratio (days to cover) | 0.21 |
Income Statement
In the last 12 months, Biofrontera had revenue of $34.07 million and -$20.13 million in losses. Loss per share was -$13.02.
| Revenue | 34.07M |
| Gross Profit | 16.63M |
| Operating Income | -22.58M |
| Pretax Income | -20.12M |
| Net Income | -20.13M |
| EBITDA | -18.59M |
| EBIT | -19.65M |
| Loss Per Share | -$13.02 |
Balance Sheet
The company has $1.42 million in cash and $5.40 million in debt, giving a net cash position of -$3.98 million or -$0.78 per share.
| Cash & Cash Equivalents | 1.42M |
| Total Debt | 5.40M |
| Net Cash | -3.98M |
| Net Cash Per Share | -$0.78 |
| Equity / Book Value | 4.79M |
| Book Value Per Share | 0.94 |
| Working Capital | 4.99M |
Cash Flow
In the last 12 months, operating cash flow was -$24.90 million and capital expenditures -$5,000, giving a free cash flow of -$24.90 million.
| Operating Cash Flow | -24.90M |
| Capital Expenditures | -5,000 |
| Free Cash Flow | -24.90M |
| FCF Per Share | -$16.10 |
Margins
Gross margin is 48.80%, with operating and profit margins of -66.26% and -59.09%.
| Gross Margin | 48.80% |
| Operating Margin | -66.26% |
| Pretax Margin | -59.04% |
| Profit Margin | -59.09% |
| EBITDA Margin | -54.55% |
| EBIT Margin | -57.67% |
| FCF Margin | -73.08% |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.29% |
| Shareholder Yield | -46.29% |
| Earnings Yield | -235.43% |
| FCF Yield | -291.20% |
Analyst Forecast
The average price target for Biofrontera is $18.00, which is 958.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.00 |
| Price Target Difference | 958.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 28.38% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Biofrontera has an Altman Z-Score of -5.66 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.66 |
| Piotroski F-Score | 3 |